Pharma Capital

Faron Pharmaceuticals boss upbeat as Phase III trial enters critical period

Dr Markku Jalkanen, chief executive of Faron Pharmaceuticals Ltd (LON:FARN) tells Proactive's Andrew Scott they're entering an exciting period for the company with recruitment for their Phase III trial for its lead drug set for completion later this year.

A positive readout for Traumakine, which is used to treat acute respiratory distress syndrome caused by pneumonia, would pave the way for its launch in Europe and the US.

Clevegen, Faron’s cancer immunotherapy, is set to undergo preclinical toxicity studies.

 

View full FARN profile

Faron Pharmaceuticals Oy Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.